| Objective: The interventional therapy of primary liver cancerresection combined with transcatheter arterial chemoembolization (TACE)and simple operation resection effect, the establishment of hepatocellularcarcinoma after hepatic arterial chemoembolization interventional therapyfor hepatocellular carcinoma and clinical application value, selection forliver cancer patients develop individualized plans. Methods: Aretrospective analysis of2009January～2011year in January theDepartment of general surgery of Yibin First People’s Hospital fromprimary liver cancer patients with limited operation in90cases, afteroperation,90cases were randomly divided into control group andobservation group, the observation group of52cases of postoperativeadjuvant TACE therapy, the remaining38patients after liver resection forhepatocellular carcinoma has not given to other treatment methods, tocontrol group. The observation group52patients within6months afteroperation rules for TACE treatment, every4Monday time, total5times.The observation group was divided into1～2month,2～3month,3～6month3sub groups, according to postoperative liver cancer in half firstimplementation of TACE treatment, including22patients in1～2monthsafter operation,17patients began in2～3months,13patients in3～6months after operation started TACE treatment the3year, the subgroup of TACE recurrence rate was two two, in order to draw liver cancerpostoperative TACE treatment group3of the optimal time. At the sametime, liver function, liver cirrhosis, there is no envelope, tumor size, AFPmay be clinical indicators of statistical research on the effects ofpostoperative recurrence of hepatocellular carcinoma, and analyze itsrelationship with tumor recurrence. Study for more than3years in90cases, establish a statistical data, respectively, in the TACE after1years,2years,3years to compare the statistical survival rate of the patient andtumor recurrence. Results: The control group and the observation groupof two patients in the clinical data of gender, age, liver function, livercirrhosis, portal vein tumor thrombus, have no envelope, tumor size, AFP,HBSAg were comparable (P>0.05). A control group of1years,2years,3year survival rates were68.4%,44.7%,31.6%; observation group of1years,2years,3year survival rates were86.5%,76.9%,61.5%; thecontrol statistical comparison of rate of survival group and observation ofpatients of two groups after, with a significant difference (P<0.05). Acontrol group of1years,2years,3years recurrence rates were42.1%,52.6%,73.7%; observation group of1years,2years,3years recurrencerates were21.2%,28.8%,44.2%; the control group and tumor recurrencerate differences between the two groups were observed after operationthere was significant (P<0.05). Observation group between clinical datawere comparable (P>0.05). There was statistical significance were observed and compared the clinical data group overall difference(X2=7.419, P=0.024); observation group1～2month,2～3month,3～6month TACE treatment within one year recurrence rate were4.5%,35.3%,38.5%;1～2month compared with2～3statistics on thetreatment of TACE with significant difference (P=0.030);1～2months3～6months compared with TACE also had statistical significance(P=0.019). The observation group and the control group in liver cirrhosis,there is no envelope, tumor size, AFP, in patients with recurrence oftumor, the difference was statistically significant (P<0.05). Conclusion:interventional therapy combined with hepatic artery embolismchemotherapy after resection of hepatocellular carcinoma (TACE) cansignificantly improve the long-term survival rate of patients, reduce therecurrence rate, improve the quality of life of patients, postoperativeTACE is safe and feasible. TACE in liver resection after1~2monthsimplementation is considered optimal time. There is relationship betweenrelapse and tumor size, capsule after liver resection for hepatocellularcarcinoma, liver cirrhosis with or without conditions, the level of AFP. |
PDF Full Text Request